CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T（CAR-T）细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
弥漫大 B 细胞淋巴瘤 CAR-T 治疗耐药生物标志物进展
英文原题：Advances in Biomarkers for CAR-T Treatment Resistance in Diffuse Large B-Cell Lymphoma.
查看英文原题
Advances in Biomarkers for CAR-T Treatment Resistance in Diffuse Large B-Cell Lymphoma.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
嵌合抗原受体（CAR）T 细胞疗法在血液系统肿瘤，尤其是弥漫性大 B 细胞淋巴瘤（DLBCL）治疗中取得重要进展。然而，DLBCL 患者接受 CAR-T 后超过 50% 仍存在耐药，耐药正逐渐成为限制疗效的主要障碍。本综述重点讨论 CAR-T 耐药机制，包括肿瘤细胞免疫逃逸、CAR-T 细胞功能障碍和肿瘤微环境（TME）作用。文章结合相关耐药机制，探索潜在耐药预测标志物，例如肿瘤细胞表面抗原、CAR-T 功能指标及 TME 中与基因突变相关的物质。对这些潜在预测标志物的探索，可为未来研究 CAR-T 治疗 DLBCL 的耐药问题提供相关启示。
展开英文摘要原文
Chimeric antigen receptor (CAR)-T cell therapy has made significant progress in treating hematologic tumors, particularly diffuse large B-cell lymphoma (DLBCL).
However, over 50% of patients are resistant after CAR-T cell therapy for DLBCL, and drug resistance is gradually becoming a major obstacle limiting its efficacy. This review primarily focuses on the mechanisms of resistance to CAR-T cell therapies, including immune escape of tumor cells, CAR-T cell dysfunction, and the tumor microenvironment (TME).
It explores potential predictive markers of resistance in the context of relevant resistance mechanisms, such as tumor cell surface antigens, CAR-T cell function, and gene mutation-related substances within the tumor microenvironment. The exploration of these potential predictive markers yields some relevant insights for future studies on resistance to CAR-T in the treatment of DLBCL.
论文信息
- 作者
- Yi SQ、Chen LL、Xv L、Fu QJ、Liu YZ、Zhang Y、Jia MX、Tong XM
- 第一作者单位
- School of Pharmacy, Hangzhou Normal University, Hangzhou, Zhejiang, 311121, China.China
- 通讯作者单位
- Hangzhou First People's Hospital, Affiliated Westlake University, Hangzhou, Zhejiang, 310006, China.China
- 文献类型
- 综述
- 期刊
- Mini reviews in medicinal chemistry2026
- 原文标识
- PubMed 42163764 · DOI 10.2174/0113895575404134251003065725